PETITION: Pres.
PETITION: Pres.
Thefirst-in-human, universal chimeric receptor antigen (CAR) T-cell (CAR-T)therapy GC027 was tolerable and resulted in antileukemic responses amongpatients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL),according to results from a phase 1 trial presented at the American Associationfor Cancer Research (AACR) Virtual Annual Meeting I 2020.1 Theuniversal CAR T cells target CD7, which, according to Xinxin Wang, PhD, ofGracell Biotechnologies Co, Ltd, in China, and lead author and presenter of thestudy, is a good target for T-ALL because it is expressed by more than 95% ofT-ALL patients. GC027 isallogeneic, which may prevent the development of graft-versus-host disease. Theproduct is introduced using lentivirus for rapid elimination of T-ALL cells.
For Immediate Release: April 22, 2020 Today, the U.S. Food and Drug Administration granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body. Patients must have received at least two prior therapies before taking Trodelvy.
TYLER, Texas (ChurchMilitant.com) - The bishop of Tyler, Texas has issued a pastoral letterrousing Catholics to understandthe mortal dangerof any coronavirusvaccine developed using stem cells from aborted babiesand is urgingthemto fight. Announcing his April 23 letter, Bp. Joseph Strickland encouraged "all who believe in the Sanctity of Life in the womb" to reflect on his message, as "it is critical for the whole human family." In the letter, Strickland explainedthat the pandemichas opened his eyes to the dangerousreality ofthe "use of in line stem cells from aborted babies in developing vaccines." "I urge you to join me, NOW, in passionately but prayerfully speaking out against this practice," he urged
SILVER SPRING, Md., April 22, 2020 /PRNewswire/ --Today, the U.S. Food and Drug Administration granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body.
NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.
PETITION: Pres. Trump don't give federal funds to COVID-19 vaccines made from aborted baby cellsSign the petition here.
NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027. Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.
Phase 2 study of cell therapy in trauma expands Companys clinical programs focused on critical care Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S.
SUZHOU, Chinaand SHANGHAI, April 13, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd.
Recent Comments